[1]
|
张晓菊.《肺结节诊治中国专家共识(2018版)》解读[J]. 中华实用诊断与治疗杂志, 2019, 33(1): 1-3. https://doi.org/10.13507/J.Issn.1674-3474.2019.01.001
|
[2]
|
许双燕, 冯涛, 曹宏伟, 等. 三维CT定量及定性参数与纯磨玻璃结节样肺腺癌TOP2A、BASP1、FAM72蛋白表达的相关性研究[J]. 放射学实践, 2022, 37(5): 543-549. https://doi.org/10.13609/J.Cnki.1000-0313.2022.05.002
|
[3]
|
Young, H.K., Mog, Y.S., Soo, K.L., et al. (2007) Persistent Pulmonary Nodular Ground-Glass Opacity at Thin-Section CT: Histopathologic Comparisons. Radiology, 245, 267-275. https://doi.org/10.1148/radiol.2451061682
|
[4]
|
宋勇, 姚艳雯. 肺部小结节的诊断和治疗近况[J]. 中华肺部疾病杂志(电子版), 2012, 5(4): 295-299.
|
[5]
|
Annemie, S., Pieter, R., Damien, D., et al. (2018) Evaluation of the Solitary Pulmonary Nodule: Size Matters, but Do Not Ignore the Power of Morphology. Insights into Imaging, 9, 73-86. https://doi.org/10.1007/s13244-017-0581-2
|
[6]
|
Cho, J.H., Oezkan, F., Koenig, M., Otterson, G.A., Herman, J.G. and He, K. (2017) Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. Current Pharmacology Reports, 3, 360-373. https://doi.org/10.1007/s40495-017-0110-5
|
[7]
|
Osarogiagbon, R.U., Veronesi, G., Fang, W., Ekman, S., Suda, K., Aerts, J.G. and Donington, J. (2019) Early-Stage NSCLC: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology, 14, 968-978. https://doi.org/10.1016/j.jtho.2019.02.029
|
[8]
|
杜孝敬, 马礼兵. 生物标志物用于鉴别诊断肺结节性质的研究进展[J]. 临床肺科杂志, 2022, 27(3): 449-453.
|
[9]
|
任雪珠, 张树森, 蔡志刚, 等. RASSF1A和SHOX2基因甲基化检测联合快速现场细胞学评价对肺癌的诊断价值[J]. 天津医药, 2022, 50(3): 319-323.
|
[10]
|
马晓阳, 张爽, 江泽友. 非小细胞肺癌中CDO1、RASSF1A和SHOX2基因甲基化的应用[J]. 临床与实验病理学杂志, 2020, 36(10): 1175-1179. https://doi.org/10.13315/J.Cnki.Cjcep.2020.10.009
|
[11]
|
Walter, R.F.H., Rozynek, P., Casjens, S., Werner, R., Mairinger, F.D., Speel, E.J.M., Zur Hausen, A., Meier, S., Wohlschlaeger, J., Theegarten, D., Behrens, T., Schmid, K.W., Brüning, T. and Johnen, G. (2018) Methylation of L1RE1, RARB, and RASSF1 Function as Possible Biomarkers for the Differential Diagnosis of Lung Cancer. PLOS ONE, 13, e0195716. https://doi.org/10.1371/journal.pone.0195716
|
[12]
|
钟彤, 杨双强. SHOX2基因甲基化与肺癌[J]. 临床肺科杂志, 2017, 22(7): 1331-1334.
|
[13]
|
刘强, 王帅, 裴国田, 等. 矮小同源盒基因启动子区域甲基化诊断肺癌价值的Meta分析[J]. 中国肺癌杂志, 2021, 24(7): 490-496.
|
[14]
|
Vo, L.T., Thuan, T.B., Thu, D.M., Uyen. N.Q., Ha, N.T. and To, T.V. (2013) Methylation Profile of BRCA1, RASSF1A and ER in Vietnamese Women with Ovarian Cancer. Asian Pacific Journal of Cancer Prevention, 14, 7713-7718. https://doi.org/10.7314/APJCP.2013.14.12.7713
|
[15]
|
Zhao, J., Cui, X., Huang, X., Lu, R., Chen, P. and Zhang, Z. (2019) Methylation of RUNX3 and RASSF1A and the Risk of Malignancy in Small Solitary Pulmonary Nodules. Journal of Cancer Research and Therapeutics, 15, 899-903. https://doi.org/10.4103/jcrt.JCRT_790_18
|
[16]
|
Dammann, R., Li, C., Yoon, J.H., Chin, P.L., Bates, S. and Pfeifer, G.P. (2000) Epigenetic Inactivation of a RAS Association Domain Family Protein from the Lung Tumour Suppressor Locus 3p21.3. Nature Genetics, 25, 315-319. https://doi.org/10.1038/77083
|
[17]
|
Schotten, L.M., Darwiche, K., Seweryn, M., Yildiz, V., Kneuertz, P.J., Eberhardt, W.E.E., Eisenmann, S., Welter, S., Sisson, B.E., Pietrzak, M., Wiesweg, M., Ploenes, T., Hager, T., He, K., Freitag, L., Aigner, C., Taube, C. and Oezkan, F. (2021) DNA Methylation of PTGER4 in Peripheral Blood Plasma Helps to Distinguish between Lung Cancer, Benign Pulmonary Nodules and Chronic Obstructive Pulmonary Disease Patients. European Journal of Cancer, 147, 142-150. https://doi.org/10.1016/j.ejca.2021.01.032
|
[18]
|
郭婧瑶, 骆莹滨, 吴建春, 等. 肺磨玻璃结节患者血清炎症因子及髓源性抑制细胞的表达水平及临床意义[J]. 中国肿瘤临床, 2022, 49(13): 693-698.
|
[19]
|
周淼, 闫五玲, 赵栋梁, 等. SHOX2和RASSF1A基因组合甲基化检测参与诊断的肺结节1例假阴性分析[J]. 中国当代医药, 2021, 28(2): 201-204.
|
[20]
|
李星月, 殷一行, 袁璐, 等. 肺癌筛查及肺结节随访管理的循证证据总结[J]. 现代预防医学, 2023, 50(20): 3734-3741. https://doi.org/10.20043/J.Cnki.MPM.202303390
|
[21]
|
Weiss, G., Schlegel, A., Kottwitz, D., et al. (2017) Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease. Journal of Thoracic Oncology, 12, 77-84. https://doi.org/10.1016/j.jtho.2016.08.123
|
[22]
|
Chung, K., Jacobs, C., Scholten, E.T., et al. (2017) Lung-RADS Category34X: Does It Improve Prediction of Malignancy in Subsolid Nodules. Radiology, 284, 264-271. https://doi.org/10.1148/radiol.2017161624
|
[23]
|
中国医药教育协会肺癌医学教育委员会. 肺结节多学科微创诊疗中国专家共识[J/OL]. http://gfffgbb8353bb55a248bbhupkw0qpckv066x5q.fffg.dali.cwkeji.cn/kcms/detail/51.1492.r.20230705.1321.030.html, 2024-01-03.
|
[24]
|
杨德平, 张萍, 金慧敏, 等. SHOX2、PTGER4基因甲基化和SCC联合检测在肺癌诊断中的应用[J]. 检验医学与临床, 2021, 18(8): 1101-1104.
|
[25]
|
Bernd, S., Volker, L., Dimo, D., et al. (2010) SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer Based on Bronchial Aspirates. BMC Cancer, 10, Article No. 600. https://doi.org/10.1186/1471-2407-10-600
|
[26]
|
Hong, C., Makoto, S., Yohko, N., et al. (2006) Aberrant Methylation of RASGRF2 and RASSF1A in Human Non-Small Cell Lung Cancer. Oncology Reports, 15, 1281-1285.
|
[27]
|
Kneip, C., Schmidt, B., Seegebarth, A., et al. (2011) SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma. Journal of Thoracic Oncology, 6, 1632-1638. https://doi.org/10.1097/JTO.0b013e318220ef9a
|
[28]
|
朱玲, 任德旺, 马润阳, 等. 良恶性肺疾病组织前列腺素E受体4基因甲基化水平变化及其诊断价值研究[J]. 标记免疫分析与临床, 2023, 30(5): 748-752 757.
|
[29]
|
Xu, Z., Wang, Y., Wang, L., Xiong, J., Wang, H., Cui, F. and Peng, H. (2020) The Performance of the SHOX2/PTGER4 Methylation Assay Is Influenced by Cancer Stage, Age, Type and Differentiation. Biomarkers in Medicine, 14, 341-351. https://doi.org/10.2217/bmm-2019-0325
|
[30]
|
初霞, 王保健, 赵伟, 等. 血浆SHOX2和PTGER4基因甲基化在肺癌筛查中的意义[J]. 中华保健医学杂志, 2021, 23(5): 488-491.
|